Trial reportJPEN. Journal of parenteral and enteral nutrition2020
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.
Trial report in JPEN. Journal of parenteral and enteral nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome
Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026Trial
- Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.Journal of pediatric gastroenterology and nutrition · 2026Trial
- Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.JPEN. Journal of parenteral and enteral nutrition · 2022Trial
- Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.JPEN. Journal of parenteral and enteral nutrition · 2022Trial
- A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026Article
- Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment.BMC pediatrics · 2026Article
- Quality of life of children with short bowel syndrome and their caregivers from the perspective of caregivers: a cross-sectional study in China.European journal of pediatrics · 2026Article
- Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance.Advances in therapy · 2026Article
- Article
- Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis.Pakistan journal of medical sciences · 2025Review
- Three-year experience with GLP-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome.Pediatric surgery international · 2025Article
- Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.BMJ open gastroenterology · 2025Article
- A cross-sectional observational study of quality of life in adult short bowel syndrome patients: What role does autologous gut reconstruction play?Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025Observational
- Plasma glucagon-like peptide-2 in cats with chronic enteropathies.Journal of feline medicine and surgery · 2025Article
- Pediatric Chronic Intestinal Failure: Something Moving?Nutrients · 2024Review
- Plasma glucagon-like peptide-2 concentrations are lower in dogs with chronic enteropathies than in healthy dogs.American journal of veterinary research · 2023Article
- Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study.Nutrients · 2023Article
- Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome: A multinational, noninterventional, cross-sectional survey.JPEN. Journal of parenteral and enteral nutrition · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTeduglutide reduces or eliminates parenteral support (PS) dependency in patients with short bowel syndrome (SBS). Recent post hoc analyses demonstrated that effects are correlated with baseline PS volume. We assessed the SBS-related quality-of-life (QoL) impact of teduglutide, particularly whether improvements are greater among subgroups achieving more PS volume reduction.
methodsUsing phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome-Quality of Life (SBS-QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiology, and bowel anatomy. Generalized estimating equation models were fitted to assess impact of teduglutide on SBS-related QoL using data from all visits, adjusted for baseline characteristics.
resultsOf 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively). In adjusted analyses, teduglutide had a nonsignificant reduction (improvement) of -8.6 points (95% CI: 2.6 to -19.8) in SBS-QoL sum score from baseline to Week-24 vs placebo. The impact of teduglutide varied by subgroup. Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9). Results were similar for SBS-QoL subscale and item scores.
conclusionsThe impact of teduglutide treatment on SBS-related QoL vs placebo varied among subgroups and was significant and most pronounced among patients with highest baseline PS volume requirement or IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.